EndoGastric Solutions Revenue and Competitors

Seattle, WA USA

Location

#6381

Growjo Ranking

Estimated Revenue & Valuation

  • EndoGastric Solutions's estimated annual revenue is currently $25.4M per year.(i)
  • EndoGastric Solutions's estimated revenue per employee is $251,000
  • EndoGastric Solutions's total funding is $362.2M.

Employee Data

  • EndoGastric Solutions has 101 Employees.(i)
  • EndoGastric Solutions grew their employee count by 3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$44.9M143-30%$211.3MN/A
#2
$54M17211%$35.5MN/A
#3
$5.3M210%N/AN/A
#4
$18.3M73N/AN/AN/A
#5
$7.8M31-16%N/AN/A
#6
$58M23113%N/AN/A
#7
$6M24-11%N/AN/A
#8
$8M3210%N/AN/A
#9
$198.5M7913%N/AN/A
#10
$6.3M5025%$27.5MN/A
Add Company

About EndoGastric Solutions: Based in Redmond, WA, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure—a barely invasive solution that addresses a significant unmet clinical need. About Transoral Incisionless Fundoplication (TIF®) procedure for reflux: Performed without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical repair another treatment option to correct the underlying cause of GERD. Studies show that for up to three years after the TIF procedure esophageal inflammation (esophagitis) is eliminated and most patients are able to stop using daily PPI medications to control symptoms. To locate a physician visit GERDHelp.com. About EsophyX® technology: The original EsophyX device was cleared by the FDA in 2007. EGS launched the third generation EsophyX device, the EsophyX Z in 2015. The technology has continued to evolve and is a clinically-backed tool for physician use in the treatment of GERD. The EsophyX technology now enables surgeons and gastroenterologists to use a wider selection of endoscopes–including low profile and larger high-definition models—to treat the underlying anatomical cause of GERD. The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids from washing back up into the esophagus. The device is inserted through the patient's mouth with direct visual guidance from an endoscope.

keywords:N/A

$362.2M

Total Funding

101

Number of Employees

$25.4M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

EndoGastric Solutions News

2022-04-17 - Europe Gerd And Nerd Treatment Market Business ...

EndoGastric Solutions EndoStim GlaxoSmithKline. Ironwood Pharmaceuticals Jeil pharmaceutical. Johnson & Johnson Mederi Therapeutics Medigus

2022-04-17 - Global Gastroesophageal Reflux Disease Treatment Device ...

... Device Market Share 2022-2028 With Top Countries Data | Key-players- B,MEDERI THERAPEUTICS, Medigus Lt,Torax , EndoGastric Solutions.

2022-04-06 - Global Gastro Esophageal Reflux Disease Drug and Devices ...

Endogastric Solutions; Medigus; Medtronic; Carbon Medical technologies; Johnson & Johnson. It is also categorized into various geographies:.

2019-05-31 - Seattle VC Watch: EndoGastric, Dolly, MDmetrix, SeekOut & More

Share Share on Facebook Share on Twitter LinkedIn Email Reprints Let’s catch up on some of the notable funding rounds raised by Seattle-area tech and life sciences companies in May: —EndoGastric Solutions, a Redmond-based business developing minimally invasive medical devices, said it raised $ ...

2019-05-30 - Seattle medical device firm EndoGastric Solutions closes $45M round for acid reflux treatment

(EndoGastric Image) EndoGastric Solutions, a medical technology company focused on acid reflux, has closed a $45 million financing round to grow the reach of its non-invasive treatment. The Series I round includes $30.5 million in funding that was announced last summer as well as a $14.5 millio ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M10255%N/A
#2
$25.6M102-25%N/A
#3
$25.7M1059%N/A
#4
$15.4M106-32%N/A
#5
$16.1M1070%N/A